// App-Quantinova.ai

PB1471 : LONG-TERM EFFECTS IN SUBGROUPS OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN VERSUS ECULIZUMAB: 48-WEEK ANALYSIS OF PEGASUS PHASE 3 TRIAL

Researchers

Presenter

  • Regis Peffault de Latour

Principal Investigators

  • Carlos M. de Castro

  • Jeffrey Szer

  • Kensuke Usuki

  • Peter Hillmen

  • Morag Griffin

  • Mohammed Al-Adhami

  • Crystal Chen

  • Hisakazu Nishimori

  • Ilene C. Weitz

Medical Centers

  • Jane Anne Nohl Division of Hematology,Keck-USC School of Medicine,Los Angeles, CA,United States

  • Royal Melbourne Hospital, Melbourne, Australia

  • Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

  • Duke University, Durham, North Carolina, United States

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

  • Department of Obstetrics and Gynecology, Tokai Univeresity Hospital, Kanagawa, Japan

  • Apellis Pharmaceuticals, Inc.,Waltham,United States

  • Department of Clinical Haematology,Peter MacCallum Cancer Centre &amp

Locations

  • United States

  • Australia

  • Japan

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03500549

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved